~~<i id='1A4B96286A'><strike id='1A4B96286A'><tt id='1A4B96286A'><pre id='1A4B96286A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

comprehensive

author：knowledge 2025-09-14 11:49:15 - browse：12465

WASHINGTON — Back in 1980, when the Food and Drug Administration approved the use of lead acetate in hair dyes, little was known about the way skin absorbs toxic chemicals.

The skin — and the scalp in particular — were considered tough barriers to break, and many public health officials believed that even if small amounts of lead got through, or were inhaled, it couldn’t really hurt anyone.

But in science, 37 years is an eon. So a coalition of environmental groups, academics, and consumer advocates is pushing FDA to take lead acetate off the market. It is now permitted as a color additive.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Paying for Covid pills will soon shift to insurers

entertainment

knowledge

focus

hotspot

focus

LAURIEDIEFFEMBACQ/BELGAMAG/AFPviaGettyImagesEveryoneknowstheuniversalsymbolofbreastcancer:thepinkrib

WSS

CDC recommends rationing of RSV shot due to shortages

Paying for Covid pills will soon shift to insurers

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

Doctors in states that ban abortion can still help patients

Maker of FluMist seeks to allow at

Diversifying clinical trials isn't enough to close racial gaps: study

focus

comprehensive

entertainment

Anesthesiologist group: stop taking Ozempic before surgery

Teacher posts viral 'school supply rant' with advice for parents

Jerome Adams on the need for new antivirals for Covid

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Tori Bowie and the unacceptable rates of Black maternal death

Meta's Zuckerberg and Chan on track to put $50 billion into science

Medical records are filled with copy

Biden's order seeks to regulate AI risk without stifling innovation

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

'Weather

knowledge

Why Sanofi got shellacked over its spinoff

First Opinion Podcast: How to protect health care in times of war

Readout Newsletter: What happened with Sarepta's Duchenne data

Traditional Chinese medicine benefits explored in new JAMA study

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Why Sanofi got shellacked over its spinoff

focus

hotspot

focus

focus